This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ATRS Antares Pharma (ATRS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Antares Pharma Stock (NASDAQ:ATRS) 30 days 90 days 365 days Advanced Chart Get Antares Pharma alerts:Sign Up Key Stats Today's Range$5.59▼$5.5950-Day Range$5.59▼$5.5952-Week Range$3.11▼$5.60Volume6 shsAverage Volume3.29 million shsMarket Capitalization$955.06 millionP/E Ratio23.29Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. Read More Antares Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreATRS MarketRank™: Antares Pharma scored higher than 38% of companies evaluated by MarketBeat, and ranked 702nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Antares Pharma. Earnings and Valuation3.1 / 5Proj. Earnings Growth175.00% Earnings GrowthEarnings for Antares Pharma are expected to grow by 175.00% in the coming year, from $0.08 to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.85.Price to Book Value per Share RatioAntares Pharma has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATRS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAntares Pharma does not currently pay a dividend.Dividend GrowthAntares Pharma does not have a long track record of dividend growth. Sustainability and ESG3.6 / 5Environmental Score-2.07 Short InterestThere is no current short interest data available for ATRS. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for ATRS on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Antares Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Antares Pharma is held by insiders.Percentage Held by Institutions50.41% of the stock of Antares Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Antares Pharma's insider trading history. Receive ATRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRS Stock News HeadlinesBest Healthcare Penny StocksSeptember 18, 2024 | benzinga.comAntares Vision SpA AVJanuary 23, 2024 | morningstar.comMBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. | Crypto 101 Media (Ad)Antares Vision Share Price (AV.MI)December 7, 2023 | lse.co.ukAprea Therapeutics’ Promising Clinical Data and Distinctive Drug Profile: An Analysis of Jason McCarthy’s Buy RatingOctober 19, 2023 | markets.businessinsider.comAntares Reaches New 52-Week High (AIS)September 3, 2023 | thestreet.comAntares Vision SpA (ANV)August 2, 2023 | investing.comCOP Syringes Market Competitive Situation By 2030April 27, 2023 | marketwatch.comSee More Headlines ATRS Stock Analysis - Frequently Asked Questions How were Antares Pharma's earnings last quarter? Antares Pharma, Inc. (NASDAQ:ATRS) announced its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million. Antares Pharma had a trailing twelve-month return on equity of 7.43% and a net margin of 21.90%. What other stocks do shareholders of Antares Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Meta Platforms (META) and Prospect Capital (PSEC). Company Calendar Last Earnings11/04/2021Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ATRS CIK1016169 Webwww.antarespharma.com Phone(609) 359-3020Fax302-655-5049Employees201Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.24 Trailing P/E Ratio23.29 Forward P/E Ratio69.88 P/E GrowthN/ANet Income$46.29 million Net Margins21.90% Pretax Margin29.84% Return on Equity7.43% Return on Assets4.92% Debt Debt-to-Equity Ratio0.10 Current Ratio3.08 Quick Ratio2.87 Sales & Book Value Annual Sales$183.98 million Price / Sales5.19 Cash Flow$0.13 per share Price / Cash Flow43.89 Book Value$1.03 per share Price / Book5.43Miscellaneous Outstanding Shares170,852,000Free Float160,772,000Market Cap$955.06 million OptionableOptionable Beta1.15 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ATRS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antares Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antares Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.